We assumed that if there are no atheroprotective effects associated with the observed gene expression changes in CD68+ cells, then the fraction of atherosclerosis/CAD risk SNPs within monocyte eQTLs for the 213 lipid lowering-responsive genes should be the same as the fraction of atherosclerosis/CAD SNPs within all monocyte eQTLs. This evidence concerns the gene CD68 and coronary artery disorder.